This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Will ETFs Gain on AstraZeneca's Latest Covid-19 Vaccine Update?
by Sweta Jaiswal, FRM
Investors are closely tracking the progress in coronavirus vaccine development amid the pandemic's renewed resurgence thanks to multiple mutants.
Pharma ETFs in Focus Post Q4 Earnings
by Sweta Killa
Healthcare Q4 results seem robust given that it is the fourth-best sector from a revenue growth look and the sixth-strongest in terms of earnings growth.
ETFs to Tap AstraZeneca Mega-Deal to Buy Alexion
by Sweta Killa
AstraZeneca has agreed to buy rare-disease specialist Alexion Pharmaceuticals for $39 billion. The deal would represent the biggest transaction in pharmaceuticals since 2019.
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
ETFs to Shine on Lilly's Coronavirus Antibody Progress
by Sweta Jaiswal, FRM
Eli Lilly's (LLY) progress in antibodies treatment is expected to raise investors' optimism.
3 Reasons to Bet on Healthcare ETFs
by Sanghamitra Saha
The broader medical sector should be in the spotlight now on hopes of a coronavirus vaccine and the likelihood of a divided congress.
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Here's Why Healthcare ETFs Are Rallying Post Elections
by Sweta Jaiswal, FRM
Easing worries regarding major policy changes are driving the relief rally in the healthcare and biotech spaces in the post-election period.
Q3 Earnings Fail to Impress Pharma ETFs
by Sweta Killa
The slew of Q3 results have led to mixed trading in pharma ETFs over the past month.
ETFs to Shine on Lilly's U.S. Deal for Coronavirus Antibody
by Sweta Jaiswal, FRM
Eli Lilly's (LLY) progress in antibodies treatment is expected to raise investors' optimism.
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Pharma ETFs to Benefit from Lilly's Coronavirus Antibody Progress
by Sweta Jaiswal, FRM
Lilly's progress in antibodies treatment is expected to raise investors optimism.
ETFs to Gain as AstraZeneca Resumes Coronavirus Vaccine Trial
by Sweta Jaiswal, FRM
AstraZeneca's resumption of the late-stage trials can revive investors optimism surrounding the coronavirus vaccine development.
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Pharma ETFs Soar on Robust Q2 Earnings
by Sweta Killa
Total earnings of 66.4% of the healthcare market capitalization that has reported so far are up 4.4% on revenue growth of 4%.
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
COVID-19 Vaccine Push Brings Hope: Stock & ETF Beneficiaries
by Sanghamitra Saha
There are at least a hundred candidates in the COVID-19 vaccine race globally. However, few companies like Moderna, Pfizer and AstraZeneca are showing considerable hope.
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
by Zacks Equity Research
Sector ETF report for PPH
Top-Ranked ETFs & Stocks to Buy From Bargain Industries
by Sweta Killa
Given recovering fundamentals, investors should take advantage of the beaten-down prices. For them, we have highlighted four solid ETF & stock picks each from the industries that are currently undervalued and have a solid Zacks Rank.
Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?
by Sweta Killa
Sector ETF report for PPH